DBV Technologies (DBVT) EBITDA (2014 - 2026)
DBV Technologies (DBVT) reported EBITDA of -$52.0 million for Q1 2026, down 97.72% year-over-year from -$2.3 billion in Q1 2025, and down 15.35% on a QoQ basis from -$45.1 million in Q4 2025.
DBV Technologies (DBVT) has 12 years of EBITDA data on file, last reported at -$52.0 million in Q1 2026.
- Quarterly EBITDA fell 97.72% year-over-year to -$52.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$165.9 million (down 45.74% YoY) and the FY2025 annual result came in at -$140.2 million, down 18.82% from the prior year.
- EBITDA slipped to -$52.0 million in Q1 2026 per DBVT's latest filing, from -$45.1 million in the prior quarter.
- Across five years, EBITDA topped out at -$4.9 million in Q4 2023 and bottomed at -$52.0 million in Q1 2026.
- The 5-year median for EBITDA is -$26.8 million (2024), against an average of -$28.3 million.
- The widest annual swing landed in 2023, when EBITDA surged 73.88%; it then tumbled 442.97% in 2024.
- Tracing DBVT's EBITDA over 5 years: stood at -$18.9 million in 2022, then surged by 73.88% to -$4.9 million in 2023, then plunged by 442.97% to -$26.8 million in 2024, then tumbled by 67.96% to -$45.1 million in 2025, then declined by 15.35% to -$52.0 million in 2026.
- Per Business Quant, the three latest DBVT EBITDA figures stand at -$52.0 million (Q1 2026), -$45.1 million (Q4 2025), and -$34.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.00 Mn |
| Dec 31, 2025 | -45.08 Mn |
| Sep 30, 2025 | -34.00 Mn |
| Jun 30, 2025 | -34.84 Mn |
| Mar 31, 2025 | -26.30 Mn |
| Dec 31, 2024 | -26.84 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -34.05 Mn |
| Mar 31, 2024 | -30.43 Mn |
| Dec 31, 2023 | -4.94 Mn |
| Sep 30, 2023 | -20.66 Mn |
| Jun 30, 2023 | -24.48 Mn |
| Mar 31, 2023 | -16.98 Mn |
| Dec 31, 2022 | -18.92 Mn |
| Sep 30, 2022 | -32.67 Mn |
| Jun 30, 2022 | -34.23 Mn |
| Mar 31, 2022 | -18.62 Mn |
| Dec 31, 2021 | -16.24 Mn |
| Sep 30, 2021 | -27.73 Mn |
| Jun 30, 2021 | -27.82 Mn |
| Mar 31, 2021 | -38.28 Mn |
| Dec 31, 2020 | -29.39 Mn |
| Sep 30, 2020 | -17.83 Mn |
| Jun 30, 2020 | -42.07 Mn |
| Mar 31, 2020 | -46.79 Mn |
| Sep 30, 2019 | -131.19 Mn |
| Dec 31, 2018 | -55.59 Mn |
| Sep 30, 2018 | -51.14 Mn |
| Jun 30, 2016 | -55.79 Mn |
| Dec 31, 2015 | -16.35 Mn |
| Jun 30, 2015 | -16.49 Mn |
| Dec 31, 2014 | -15.10 Mn |
| Jun 30, 2014 | -16.57 Mn |